You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 7,727,981


✉ Email this page to a colleague

« Back to Dashboard


Title:Benzamides and related inhibitors of factor Xa
Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Inventor(s): Zhu; Bing-Yan (Belmont, CA), Zhang; Penglie (Foster City, CA), Wang; Lingyan (Chatham, NJ), Huang; Wenrong (Cupertino, CA), Goldman; Erick A. (San Francisco, CA), Li; Wenhao (South San Francisco, CA), Zuckett; Jingmei (Glendale, AZ), Song; Yonghong (Foster City, CA), Scarborough; Robert M. (Half Moon Bay, CA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Filing Date:Oct 25, 2007
Application Number:11/924,480
Claims:1. A compound of formula Ic or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof: A-Q-D-E-G-J-X (Ic) wherein: A is selected from the group consisting of: ##STR00608## ##STR00609## ##STR00610## Q is a direct link; D is selected from the group consisting of: ##STR00611## E is --C(.dbd.O)NH--; G is selected from the group consisting of: ##STR00612## G is substituted by 0-2 R.sup.1d groups and each R.sup.1d group is independently selected from the group consisting of H, --CH.sub.3, --CF.sub.3, --Cl, --F, --Br, --NH.sub.2, --N(CH.sub.3).sub.2, --OH, --OCH.sub.3, --NHSO.sub.2CH.sub.3, --NO.sub.2, --CN, --C(.dbd.O)--OCH.sub.3, --CO.sub.2H, --CONH.sub.2, --SO.sub.2NH.sub.2, --SO.sub.2CH.sub.3, --NHC(.dbd.O)CH.sub.3, --C(.dbd.O)N(--CH.sub.3).sub.2, --CH.sub.2NH.sub.2, --CH.sub.2N(--CH.sub.3).sub.2, --CH.sub.2OH, --OCH.sub.2CO.sub.2H, --OCH.sub.2C(.dbd.O)--OCH.sub.3, --OCH.sub.2C(.dbd.O)--NH.sub.2 and --OCH.sub.2C(.dbd.O)N(--CH.sub.3).sub.2, ##STR00613## ##STR00614## J is --C(.dbd.O)NH-- X is selected from the group consisting of: ##STR00615## ##STR00616## ##STR00617##

2. The compound of claim 1, wherein A is selected from the group consisting of ##STR00618##

3. A compound of formula Ic-A or Ic-B, or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof: ##STR00619## wherein A-Q is selected from the group consisting of: ##STR00620## ##STR00621## R.sup.1a is selected from the group consisting of: H, --F, --Cl, and --Br; R.sup.1d is selected from the group consisting of: H, --F, --Cl, --Br, and --OCH.sub.3; R.sup.1e1 is selected from the group consisting of: H, --F, --Cl, --Br, --NH.sub.2, --CH.sub.2NH.sub.2, --OCH.sub.3, --OH, --CN, --SO.sub.2CH.sub.3, and --SO.sub.2NH.sub.2; and R.sup.1e2 is selected from the group consisting of: H, --F, --Cl, --Br, and --NH.sub.2.

4. A compound of formula Ic-C or Ic-D, or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof: ##STR00622## wherein: A-Q is selected from the group consisting of: ##STR00623## ##STR00624## where A-Q- is optionally further substituted with at least one Z' group, where each Z' group is independently a C.sub.1-C.sub.6 alkyl optionally substituted with a hydroxyl, carboxylic acid or carboxylic acid C.sub.1-C.sub.6 ester group; R.sup.1a is selected from the group consisting of: H, --F, --Cl, and --Br; R.sup.1d1 and R.sup.1d2 are independently selected from the group consisting of: H, --F, --Cl, --Br, --CH.sub.3, --NO.sub.2, --OH, --OCH.sub.3, --NH.sub.2, --NHC(O)CH.sub.3, --NHSO.sub.2CH.sub.3, --CH.sub.2OH, and --CH.sub.2NH.sub.2; and R.sup.1e is selected from the group consisting of: --F, --Cl, --Br, --OH, --CH.sub.3, and --OCH.sub.3.

5. A compound of formula Ic-E or Ic-F, or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof: ##STR00625## wherein A-Q is selected from the group consisting of: ##STR00626## ##STR00627## R.sup.1a is selected from the group consisting of: H, --F, --Cl, and --Br; and R.sup.1d is selected from the group consisting of: H, --F, --Cl, --Br, and --OCH.sub.3.

6. A compound of formula Ic-G or Ic-H, or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof: ##STR00628## wherein: R is --SO.sub.2NH.sub.2 or --SO.sub.2CH.sub.3; R.sup.1a is selected from the group consisting of: H, --F, --Cl and --Br; E is --C(.dbd.O)NH--; J is --C(.dbd.O)NH--; R.sup.1d1 and R.sup.1d2 are independently selected from the group consisting of: H, --F, --Cl, --Br, --CH.sub.3, --NO.sub.2, --OH, --OCH.sub.3, --NH.sub.2, --NHC(O)CH.sub.3, --NHSO.sub.2CH.sub.3, --CH.sub.2OH and --CH.sub.2NH.sub.2; and R.sup.1e is selected from the group consisting of --F, --Cl, --Br, --CH.sub.3, and --OCH.sub.3.

7. A compound of claim 6 of formula Ic-I or Ic-J, or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof: ##STR00629## wherein R is selected from the group consisting of --SO.sub.2NH.sub.2, --SO.sub.2CH.sub.3, --CH.sub.2NH.sub.2, and --CH.sub.2N(CH.sub.3).sub.2; R.sup.1a is H or --F; R.sup.1d1 and R.sup.1d2 are independently selected from the group consisting of: H, --F, --Cl, --Br, and --OCH.sub.3; R.sup.1e is H or --OH.

8. A compound of formula Ic-K or Ic-L, or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof: ##STR00630## wherein: R is --SO.sub.2NH.sub.2 or --SO.sub.2CH.sub.3; R.sup.1a is selected from the group consisting of: H, --F, --Cl and --Br; E is --C(.dbd.O)NH--; R.sup.1d1 and R.sup.1d2 are independently selected from the group consisting of: H, --F, --Cl, --Br, --CH.sub.3, --NO.sub.2, --OH, --OCH.sub.3, --NH.sub.2, --NHC(O)CH.sub.3, --NHSO.sub.2CH.sub.3, --CH.sub.2OH and --CH.sub.2NH.sub.2; and R.sup.1e is selected from the group consisting of --F, --Cl, --Br, --CH.sub.3, and --OCH.sub.3.

9. A compound or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug thereof, which compound is selected from the group consisting of: ##STR00631## ##STR00632## ##STR00633## ##STR00634## ##STR00635## ##STR00636## ##STR00637##

10. A pharmaceutical composition for treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of any one of claims 1 and 2-9.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.